Updated Jul 16, 2026
Mercier Johanna has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $14.77M.
Johanna Mercier is the Chief Commercial Officer at Gilead Sciences, Inc., where she oversees the company's commercial strategy and operations. She has been involved in multiple SEC filings, indicating her active role in the company's financial and operational decisions.
| Role | Chief Comm & Corp Aff Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-16 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 450 | $125.40 | $56K |
| 2026-06-16 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 1.1K | $124.00 | $133K |
| 2026-06-16 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 1.5K | $123.42 | $183K |
| 2026-06-11 | GILD | GILEAD SCIENCES, INC. | F — Tax withholding / forfeiture | 1.3K | $121.48 | $163K |
| 2026-06-11 | GILD | GILEAD SCIENCES, INC. | M — Option exercise | 2.8K | — | |
| 2026-05-21 | NBIX | NEUROCRINE BIOSCIENCES INC | M — Option exercise | 3.3K | $0.00 | |
| 2026-05-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 700 | $132.75 | $93K |
| 2026-05-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 8.4K | $132.23 | $1.11M |
| 2026-05-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 11.2K | $131.19 | $1.47M |
| 2026-05-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 7.7K | $130.29 | $1.01M |
| 2026-05-18 | GILD | GILEAD SCIENCES, INC. | M — Option exercise | 25.0K | $66.64 | $1.67M |
| 2026-04-16 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale | 3.0K | $140.96 | $423K |
| 2026-03-17 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale [10b5-1] | 3.0K | $144.23 | $433K |
| 2026-03-12 | GILD | GILEAD SCIENCES, INC. | F — Tax withholding / forfeiture | 3.2K | $148.56 | $478K |
| 2026-03-12 | GILD | GILEAD SCIENCES, INC. | M — Option exercise | 6.6K | — | |
| 2026-03-02 | GILD | GILEAD SCIENCES, INC. | A — Grant or award | 11.1K | $0.00 | |
| 2026-02-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale [10b5-1] | 200 | $155.62 | $31K |
| 2026-02-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale [10b5-1] | 9.4K | $154.91 | $1.46M |
| 2026-02-18 | GILD | GILEAD SCIENCES, INC. | S — Open-market sale [10b5-1] | 18.4K | $154.18 | $2.84M |
| 2026-02-18 | GILD | GILEAD SCIENCES, INC. | M — Option exercise [10b5-1] | 25.0K | $66.64 | $1.67M |
Johanna Mercier is the Chief Commercial Officer at Gilead Sciences, Inc., where she oversees the company's commercial strategy and operations. She has been involved in multiple SEC filings, indicating her active role in the company's financial and operational decisions.…
5 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 24 open-market sales ($14.77M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Mercier Johanna profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.